Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Rupatadine Fumarate | Pafinur | "4.5. Interactions with other medicinal products 4.8 Undesirable effects" | "Interaction with midazolam hypersensitivity reactions (including anaphylactic reactions, angioedema and urticarial)" | Aug, 2024 |
| Dexmedetomidine | Precedex | "4.4 Special Warnings and Special Precautions for Use 4.8 Undesirable effects" | Multiple safety updates for pediatrics | Aug, 2024 |
| Finasteride | Proscar | 4.8 Undesirable effects | Suicidal ideation | Aug, 2024 |
| Mefenamic Acid | Ponstan | "4.4 Special Warnings and Special Precautions for Use 4.8 Undesirable effects" | Generalized bullous fixed drug eruption | Aug, 2024 |
| Rivaroxaban | Xarelto | 4.8 Undesirable effects | Anticoagulantrelated nephropathy | Aug, 2024 |
| Lanadelumab | Takhzyro | 4.8 Undesirable effects | Addition of Long-term safety data based on HELP study extension | Jul, 2024 |